Table 2.
Fold increase of IL-12p70 concentrations in response to the PRR combinations C1–C4 as compared to their respective single ligands
| Stimulated PRRs | Fold increase, IL-12p70a |
|---|---|
| Combination C1, Dectin-1 + TLR7/8 | |
| Dectin-1 | ≥170 |
| TLR7/8-0.5b | ≥125 |
| Combination C1, Dectin-1 + TLR7/8 | |
| Dectin-1 | ≥390 |
| TLR7/8-1c | 6.4 |
| Combination C2, TLR2:1 + TLR3 | |
| TLR2:1 | ≥400 |
| TLR3 | 9 |
| Combination C3, TLR2:1 + MDA5/TLR3 | |
| TLR2:1 | ≥260 |
| MDA5/TLR3 | 4.3 |
| Combination C4, TLR3 + TLR7/8d | |
| TLR3 | 11 |
| TLR7/8 | ≥680 |
aFold increase of IL-12p70 levels was calculated from the results presented in Fig. 3.
Samples with non-detectable level of IL-12p70, were given the value of the detection limit to calculate the fold increase. For these samples, the fold increase could potentially be higher, and fold increase has been set as “≥“.
bThe TLR7/8 agonist R848 was used in concentration 0.5 μg/mL.
cThe TLR7/8 agonist R848 was used in concentration 1 μg/mL.
dPoly(I:C) (TLR3) and R848 (TLR7/8) were used in concentration 20 μg/mL and 0.5 μg/mL, respectively.